O‘zbekiston кardiologiyasi Том 1 № 1 (2024) · с. 77-82

Cardioprotective approaches when prescribing iSGLT-2

Тригулова, Р, Мухтарова, Ш, Насырова, Х, Mukhtarova, SHakhnoza, Trigulova, Raisa, Nasirova, Khurshida, Mukhtarova, SHakhnoza, Trigulova, Raisa, Nasirova, Xurshida

Читать на сайте источника PDF

Аннотация

Background. Sodium-Glucose Cotransporter-2 (NGLT-2) inhibitors have gained significant attention for their cardioprotective properties. This review explores the cardiovascular benefits of NGLT-2 inhibitors, particularly their impact on heart health in patients with comorbidities such as type 2 diabetes and heart failure. The primary objective is to evaluate the mechanisms and effectiveness of these inhibitors in improving cardiovascular outcomes. Methods. A comprehensive review of relevant literature was conducted, focusing on recent studies, including clinical trials and meta-analyses, to assess the impact of NGLT-2 inhibitors on heart failure, diabetes, and associated cardiovascular events. The review examines various approaches related to the use of NGLT-2 inhibitors in treating cardiovascular conditions. Key Content and Findings. NGLT-2 inhibitors have been shown to significantly reduce the risk of cardiovascular events, including heart failure hospitalizations and mortality. Their mechanisms of action include improving glucose control, reducing kidney burden, and mitigating endothelial dysfunction. The review highlights these mechanisms and the clinical benefits in treating patients with heart failure and type 2 diabetes. Conclusion. NGLT-2 inhibitors represent a valuable treatment option for improving heart health in patients with type 2 diabetes and heart failure. Further research is needed to optimize their use and fully understand their underlying mechanisms.

NGLT-2 inhibitorscardioprotectionheart failuretype 2 diabetescardiovascular riskmetabolic modulationheart functionanti-inflammatory effectsингибиторы НГЛТ-2кардиопротекция

Источник метаданных: OAI-PMH архив журнала · Sindex не хранит полный текст, а даёт ссылку на источник.

Цитировать

APA 7 
Тригулова, Р, Мухтарова, Ш, Насырова, Х, Mukhtarova, SHakhnoza, Trigulova, Raisa, Nasirova, Khurshida, Mukhtarova, SHakhnoza, Trigulova, Raisa & Nasirova, Xurshida (2024). Cardioprotective approaches when prescribing iSGLT-2. O‘zbekiston кardiologiyasi, 1(1), 77-82.
GOST R 7.0.5 
Тригулова, Р, Мухтарова, Ш, Насырова, Х, Mukhtarova, SHakhnoza, Trigulova, Raisa, Nasirova, Khurshida, Mukhtarova, SHakhnoza, Trigulova, Raisa, Nasirova, Xurshida Cardioprotective approaches when prescribing iSGLT-2 // O‘zbekiston кardiologiyasi. 2024. Т. 1. № 1. С. 77-82.
BibTeX 
@article{р2024,
  author  = {Тригулова, Р and Мухтарова, Ш and Насырова, Х and Mukhtarova, SHakhnoza and Trigulova, Raisa and Nasirova, Khurshida and Mukhtarova, SHakhnoza and Trigulova, Raisa and Nasirova, Xurshida},
  title   = {Cardioprotective approaches when prescribing iSGLT-2},
  journal = {O‘zbekiston кardiologiyasi},
  year    = {2024},
  volume  = {1},
  number  = {1},
  pages   = {77-82}
}
RIS 
TY  - JOUR
AU  - Тригулова, Р
AU  - Мухтарова, Ш
AU  - Насырова, Х
AU  - Mukhtarova, SHakhnoza
AU  - Trigulova, Raisa
AU  - Nasirova, Khurshida
AU  - Mukhtarova, SHakhnoza
AU  - Trigulova, Raisa
AU  - Nasirova, Xurshida
TI  - Cardioprotective approaches when prescribing iSGLT-2
JO  - O‘zbekiston кardiologiyasi
PY  - 2024
VL  - 1
IS  - 1
SP  - 77
EP  - 82
ER  -